Overview
- Radical Numerics reported in late October that clinicians administered bacteriophages designed by its Omnii‑1 AI to a patient with an antibiotic‑resistant infection.
- The company says Omnii‑1 edited the phage receptor‑binding protein (gp17, the tail fiber) and that the designed cocktail eliminated the patient’s bacterial isolate in laboratory tests before treatment.
- Radical Numerics has not released clinical details or patient outcomes and no peer‑reviewed data have been published, though the company says it intends to seek publication and pursue commercialization.
- Researchers and public‑health experts have raised biosafety and dual‑use concerns about AI systems that can design or modify viral genomes and have called for independent review and stronger safeguards.
- The claim builds on earlier academic work that used AI to create phages that worked in lab bacteria, and if validated the approach could shorten time to tailored phage therapies for people with drug‑resistant infections.